Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vixarelimab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Vixarelimab is a fully human monoclonal antibody that targets the oncostatin M receptor beta subunit (OSMRβ). By binding to OSMRβ, vixarelimab inhibits signaling of both interleukin 31 (IL-31) and oncostatin M (OSM), two cytokines implicated in pruritus, inflammation, and fibrosis. This dual mechanism may provide therapeutic benefit in diseases characterized by chronic itch and fibrotic processes. Vixarelimab is being developed for several inflammatory and fibrotic conditions including prurigo nodularis, idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), ulcerative colitis, and other skin disorders. The drug was originally developed by Biogen and is currently being advanced by Genentech/Roche and Kiniksa Pharmaceuticals[1][3][4][5][6].
- Brand names
- vixarelimab
- Other names
- KPL-716KPL716KPL 716
02
Targets
OSMR (Oncostatin M receptor beta subunit)
Beyond the preview
Go deeper on vixarelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vixarelimab.